Developing new effective treatments for cancer patients

Patient and provider talking in a clinic setting

The center unites cutting-edge technologies with a multidisciplinary group of clinicians and scientists to advance drug discovery and development. OHSU is one of the few universities nationally to bring together the infrastructure to translate scientific discoveries from the lab into effective therapies for human diseases. Learn more about the center

Drug discovery and development for a range of diseases

Stem cells
  • Cancer: solid tumors and hematological malignancies
  • Drugs to treat cardiovascular diseases
  • Anti-infective agents
  • Drugs to treat neurologic disorders
  • Radiation sensitizers and protectors
  • Stem cells
  • Learn more about our work

Join us for virtual talks with experts in the field

Person talking at a virtual event

Our lecture series spotlights researchers engaged in discovering and validating therapeutic targets, biomarkers, developing novel agents and conducting clinical research. These events are free and open to the public.

Watch recordings of past events and check out what's next. 

Recent news

Shivaani Kummar, M.D., head of the division of hematology and medical oncology in the OHSU School of Medicine, and Sanjay Malhotra, Ph.D., right, are co-directors of the Knight Cancer Institute’s Center for Experimental Therapeutics. Malhotra is a professor in the departments of cell, developmental and cancer biology and oncological sciences in the OHSU School of Medicine. (OHSU/Christine Torres Hicks)

The OHSU Knight Cancer Institute’s Center for Experimental Therapeutics has been selected as the only cancer center in the Pacific Northwest to participate in a national consortium aimed at accelerating the discovery and development of new and innovative targeted cancer therapies.

Androgen deprivation therapies for prostate cancer inevitably fail, and most patients progress to metastatic and incurable castration-resistant disease. In Cell Reports Medicine, Sanjay Malhotra, Ph.D., and colleagues describe a potential new therapy for prostate cancer that acts through a mechanism independent of androgen signaling. 

Center for Experimental Therapeutics logo